COVID-PACT: What's the Best Anticoagulant Strategy for Critically Ill Patients With COVID-19?

Michelle L. O'Donoghue, MD, MPH; David D. Berg, MD, MPH

September 12, 2022

This transcript has been edited for clarity.

Michelle L. O'Donoghue, MD, MPH: Hi. I'm Dr Michelle O'Donoghue. I'm here at ESC Congress 2022. We are back in person, which is great. There's been terrific science, and one of the late-breaking clinical trials that will be presented will be by my friend and colleague, Dr David Berg, who is an investigator at the TIMI Study Group.

He presented the top-line results of a trial called COVID-PACT, on which I am a co-author. I thought it would be very interesting to talk about this topic in general, as it is still an interesting one.

Welcome, David.

David D. Berg, MD, MPH: Thank you, Michelle. It's a pleasure to be here. Thank you for having me.

O'Donoghue: Let's talk a little bit about the question being asked. Why do we think about clots in the context of COVID-19?

Berg: That's a great question. Relatively early in the pandemic, it was appreciated that patients with COVID-19 have an increased risk of developing blood clots, and that risk is particularly concentrated in patients who require ICU-level care. The exact mechanisms underpinning that increased thrombotic risk are still being sorted out, but there are probably multiple things

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.